Dr. Garcia-Manero discusses the latest updates from the COMMANDS trial. Dr. Oluwole discussed new data on brexu-cel in patients with relapsed or refractory ALL. Dr. Rodríguez-Otero shares the MRD analysis from the phase III PERSEUS trial at the 2024 ASCO Annual Meeting. The study compared treatment response based on prior systemic lines of therapy and prior BTK inhibition in patients with MCL. Julie Braish, MBBCh, discusses her study on JAK2 allele burden in myelofibrosis presented at ASCO 2024. A phase II study evaluated a combination of the IMM01 fusion protein with azacitidine in untreated MDS. A database analysis compares how much time patients spend in healthcare settings, based on receiving oral, IV, or SC HMAs. After five and a half years of follow-up, rituximab maintenance significantly improved survival outcomes. Dr. El-Jawahri discusses exciting ASCO sessions, such as the plenary session that focused on telehealth and palliative care. The study utilized three clinical trials to compare the efficacy of acalabrutinib, zanubrutinib, and ibrutinib for CLL. Dr. Furqan shared data from a retrospective analysis on patients who received pirtobrutinib prior to CAR T-cell therapy. Investigators identified pre- and postinfusion factors linked to severe hematotoxicity, as defined by EHA/EBMT criteria. Manali Kamdar, MD, shared results from the pivotal phase III TRANSFORM study on lisocabtagene maraleucel in LBCL. A retrospective study has found an association between post-CAR-T sC5b-9 levels and ICANS occurrence following CAR-T. These findings concern axi-cel use in relapsed and refractory primary and secondary disease. Dr. Costa presents subgroup findings from the single-line therapy patients in the CARTITUDE-4 phase III trial. Patients with relapsed refractory LBCL can derive clinical benefit from liso-cel NCP without compromising safety. Patients who responded to treatment achieved more than 90% bone marrow blast reduction compared with baseline. Dr. Garcia-Manero discussed the phase II ASTREON trial on myelodysplastic syndromes at the 2024 ASCO Annual Meeting.